• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

Slides for the June 3, 2009 Meeting of the Anti-Infective Drugs Advisory Committee

FDA

Joette M. Meyer, Pharm.D., Division of Special Pathogen & Transplant Products, Office of Antimicrobial Products, CDER (pdf

 

Tafadzwa Vargas-Kasambira, M.D., M.P.H., Division of Special Pathogen and Transplant Products, Office of Antimicrobial Products, CDER (pdf

 

Questions for the Committee, Edward Cox, M.D., M.P.H, Director, Office of Antimicrobial Products (pdf

 

 

SPONSORS

 

Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance

 

Kenneth G. Castro, M.D., Assistant Surgeon General, U.S. Public Health Service

Director, Division of Tuberculosis Elimination (pdf

 

Brian Woodfall, MD, Senior Director, Global Clinical Development & Medical Affairs, Tibotec (pdf

 

Charles D. Wells, MD, Director, TB Products Unit, Otsuka Pharmaceutical Development & Commercialization, Inc. (pdf)

 

Mel Spigelman, MD, Global Alliance for TB Drug Development (pdf)

 

Charles M Heilig, PhD, Tuberculosis Trials Consortium Team

Centers for Disease Control and Prevention (pdf

 

 

GUEST SPEAKERS

Carole Mitnick, Sc.D., Harvard Medical School (pdf)

 

David Cohn, MD, Denver Public Health, University of Colorado Health Sciences Center (pdf

 

 

OPEN PUBLIC HEARING

 

OPH 1 (pdf

OPH 2 (pdf